Upgrade

SciSparc Ltd.

SPRC

Last
$4.47
Day
+0.9%
1y
-89.1%
5y
-100.0%
52w
-89.9%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
—
EMA 21
4.81
EMA 50
5.33
EMA 200
13.66
20d high
-20.9%
5y high
-100.0%
5y range
0th
Website · 3 employees · Israel

Positions held

Your positions

SPRC isn't in your positions.

Add it to see shares, cost, and P&L here.

Score
-12
Hold
avoid
Signal
Sell
Target
$5.09
Stop
$3.88
Stop distance
13.2%
Target vs last
+13.9%

Fundamentals

Market cap$2.57MEnterprise value$8.14MTrailing P/E0.02Forward P/E—
PEG—Price / book0.38Beta2.55Dividend yield0.00%
Revenue growth-38.4%Earnings growth—Gross margin9.5%Operating margin-17.2%
Profit margin0.0%ROE-1.6%ROA-26.0%Debt / equity0.24
Current ratio0.87Free cash flow-$343,250Analyst recommendationnoneMean target—
52w high$43.6552w low$2.98

Quarterly

No data yet.

Yearly (6y)

20252024202320222021
Revenue$0.9M$1.3M$2.9M$1.3M—
Op margin-1022.1%-554.5%-200.5%-615.2%—
Net income-$12.2M-$6.3M-$5.1M-$2.6M—
Gross margin73.7%38.7%76.3%76.1%—
Gross profit$0.6M$0.5M$2.2M$1.0M—
Operating income-$8.7M-$7.2M-$5.8M-$8.3M—
Headline scan

No flags

• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).

News

2026-10-07 · SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture

2026-09-23 · SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

2026-09-02 · SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

2026-09-02 · SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

2026-08-31 · NeuroThera Labs Achieves Significant Enrollment Momentum in SCI210 Autism Clinical Trial

2026-08-31 · SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

2026-08-31 · Weekly Roundup on the Cannabis Sector & Psychedelic Sector

2026-08-26 · SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

2026-08-24 · SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

2026-08-18 · SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million

2026-08-12 · NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement

2026-08-12 · NeuroThera Labs Granted Japanese Patent for Its Proprietary, Innovative Therapeutic Combination

SPRC · daily-3.1% over 13 sessions
Close EMA21 EMA50 EMA200
4.134.514.905.295.672026-092026-092026-092026-092026-102026-102026-10